UCLA Health

Scientists are looking at ways to cure Hepatitis B. This study (A5368) will assess how safe and well tolerated an FDA-approved medication called cemiplimab is. It will be given as an infusion to participants with Hepatitis B who are on continuous treatment for Hepatitis B. The research suggests that cemiplimab can help the immune system clear Hepatitis B from the body. The goal is to see if this treatment helps to achieve a Hepatitis B cure.

Eligibility:

  • 18 – 70 years of age
  • Have chronic Hepatitis B infection
  • On continuous Hepatitis B treatment for at least 12 months
  • No current Hepatitis C
  • HIV negative

For more information about A5368, please contact our study team at 310-843-2015 or CAREOUTREACH@mednet.ucla.edu